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Eric Ojerholm*, Michelle Alonso-Basanta and Charles B Simone IIAbstract
Yomo and Hayashi reported results of stereotactic radiosurgery alone for brain metastases from small cell lung cancer.
This strategy aims to avoid the neurocognitive effects of whole-brain radiation therapy. However, radiosurgery alone
increases the risk of distant intracranial relapse, which can independently worsen cognition. This concern is heightened
in histologies like small cell with high predilection for intracranial spread. The majority of study patients developed new
brain disease, suggesting radiosurgery alone may not be an optimal strategy for preserving neurocognitive function in
this population. We suggest whole-brain radiation therapy should remain the standard of care for small cell lung
cancer.
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Letter to the Editor:
Yomo and Hayashi recently reported in Radiation
Oncology their experience with upfront stereotactic
radiosurgery (SRS) for brain metastases from small cell
lung cancer (SCLC) [1]. The authors should be com-
mended for this novel investigation. We agree that SRS
might play a role in SCLC, particularly for treating a
limited number of brain metastases after prior prophy-
lactic cranial irradiation or prior whole-brain radiation
therapy (WBRT). However, we echo the authors’ call
for caution in adopting SRS alone as the initial approach
for intracranial disease.
The strategy of upfront SRS is gaining increasing
prominence [2], spurred by the excellent local control
achieved with radiosurgery and by concerns about the
side effects of WBRT. These concerns are bolstered by
studies showing declines in neurocognition and quality
of life in patients receiving WBRT [3-5]. On the other
hand, increased intracranial tumor burden often drives
cognitive dysfunction [6,7], and a recognized downside
of SRS alone is high rates of distant brain relapse. This
concern is heightened in SCLC, a biologically aggressive
tumor which disseminates to the central nervous system* Correspondence: eric.ojerholm@uphs.upenn.edu
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unless otherwise stated.in approximately two-thirds of patients during the course
of their disease [8]. Yomo and Hayashi report that 20 of
41 patients (49%) developed new brain metastases after
initial SRS, and because follow-up imaging was available
in only 34 cases, this rate could be interpreted as 20 of 34
(59%). The overall outcomes from this study suggest that
radiosurgery may be a reasonable modality in well-
selected patients with SCLC. However, it is also possible
that in populations with high rates of intracranial relapse,
an SRS approach might actually hinder – rather than
help – cognitive function.
Which is more important for preserving neurocognition:
limiting the volume of irradiated brain or maximizing
intracranial tumor control? The answer is uncertain, and
ongoing studies aim to resolve this question (e.g. NAGKC
12–01 testing WBRT versus SRS alone for five or more
brain metastases and NCCTG N107C testing WBRT
versus SRS following surgical resection of a brain me-
tastasis). Should these trials favor SRS, we anticipate
increased enthusiasm for radiosurgery in all tumor
histologies – including SCLC – and Yomo and Hayashi’s
study will be an important initial report in this population.
In the meantime, however, we suggest that WBRT remain
the standard of care for patients with brain metastases
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SRS: Stereotactic radiosurgery; SCLC: Small-cell lung cancer; WBRT: Whole-brain
radiation therapy.
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